Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma

Cancer Science

Volumn 105, Issue 6, 2014, Pages 690-696

  Watanabe, Akira ^a   Suzuki, Hideki ^a   Yokobori, Takehiko ^a   Tsukagoshi, Mariko ^a   Altan, Bolag ^a   Kubo, Norio ^a   Suzuki, Shigemasa ^a   Araki, Kenichiro ^a   Wada, Satoshi ^a   Kashiwabara, Kenji ^b   Hosouchi, Yasuo ^b   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI MAEBASHI HOSPITAL   (Japan)

Author keywords

Cancer progression; Drug resistance; Extrahepatic cholangiocarcinoma; P27; Stathmin1

Indexed keywords

PACLITAXEL; PROTEIN P27; STATHMIN; STATHMIN1 PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; ASSAY; BILE DUCT CARCINOMA; CANCER CELL LINE; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DRUG RESISTANCE; EXTRAHEPATIC CHOLANGIOCARCINOMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECURRENCE FREE SURVIVAL; RNA INTERFERENCE;

CANCER PROGRESSION; DRUG RESISTANCE; EXTRAHEPATIC CHOLANGIOCARCINOMA; P27; STATHMIN1;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PACLITAXEL; PROTEIN BINDING; RNA INTERFERENCE; RNA, SMALL INTERFERING; STATHMIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84901758412     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12417     Document Type: Article

References (29)

1. Vasilieva LE, Papadhimitriou SI, Dourakis SP. Modern diagnostic approaches to cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012; 11: 349-59.
2. Skipworth JR, Olde Damink SW, Imber C, Bridgewater J, Pereira SP, Malago M. Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Aliment Pharmacol Ther 2011; 34: 1063-78.
3. Pichlmayr R, Weimann A, Klempnauer J et al. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg 1996; 224: 628-38.
4. Klempnauer J, Ridder GJ, Werner M, Weimann A, Pichlmayr R. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer 1997; 79: 26-34.
5. Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene 2007; 26: 1003-12.
6. Alli E, Yang JM, Ford JM, Hait WN. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol 2007; 71: 1233-40.
7. Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002; 62: 6864-9.
8. Ghosh R, Gu G, Tillman E et al. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate 2007; 67: 1038-52.
9. Jeon TY, Han ME, Lee YW et al. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 2010; 102: 710-8.
10. Kang W, Tong JH, Chan AW et al. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS ONE 2012; 7: e33919.
11. Singer S, Ehemann V, Brauckhoff A et al. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 2007; 46: 759-68.
12. Hsieh SY, Huang SF, Yu MC et al. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 2010; 49: 476-87.
13. Kouzu Y, Uzawa K, Koike H et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 2006; 94: 717-23.
14. Zheng P, Liu YX, Chen L et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 2010; 9: 4897-905.
15. Ogino S, Nosho K, Baba Y et al. A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am J Gastroenterol 2009; 104: 2047-56.
16. Kim JY, Harvard C, You L et al. Stathmin is overexpressed in malignant mesothelioma. Anticancer Res 2007; 27: 39-44.
17. Lin WC, Chen SC, Hu FC et al. Expression of stathmin in localized upper urinary tract urothelial carcinoma: correlations with prognosis. Urology 2009; 74: 1264-9.
18. Baldassarre G, Belletti B, Nicoloso MS et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005; 7: 51-63.
19. Nakayama K, Ishida N, Shirane M et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85: 707-20.
20. Denicourt C, Dowdy SF. Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev 2004; 18: 851-5.
21. Sobin LH, Gospodarowicz MK, Wittekind C, eds. TMN Classification of Malignant Tumors, 7th edn. Washington, DC. Wiley-Blackwell, 2009.
22. Altan B, Yokobori T, Mochiki E et al. Nuclear karyopherin-alpha2 expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and progression in gastric cancer. Carcinogenesis 2013; 34: 2314-21.
23. Suzuki S, Miyazaki T, Tanaka N et al. Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness. Ann Surg Oncol 2011; 18: 888-93.
24. Iancu-Rubin C, Atweh GF. p27(Kip1) and stathmin share the stage for the first time. Trends Cell Biol 2005; 15: 346-8.
25. Karst AM, Levanon K, Duraisamy S et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 2011; 123: 5-12.
26. Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S. Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001; 276: 48937-43.
27. Wu L, Grigoryan AV, Li Y, Hao B, Pagano M, Cardozo TJ. Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol 2012; 19: 1515-24.
28. Balachandran R, Welsh MJ, Day BW. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells. Oncogene 2003; 22: 8924-30.
29. Iancu C, Mistry SJ, Arkin S, Atweh GF. Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle. Cancer Res 2000; 60: 3537-41.